Dr. Haribabu is a PhD in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and Operations in both APIs and Oral Solids
Last 20 years, he held several leadership roles in technical and commercial operations in global multinational company - Mylan Laboratories, including the COO of Mylan India, CEO of Mylan India and Global COO of Mylan.
Responsible for >50 Mylan facilities globally managing more than 200 APIs and 15000 SKUs of different formulations
At Mylan, he led Mylan’s foray into the ARV business and grew this business to over $800mn franchise with global leadership (in volume, value and portfolio spread) and more than 50% market share
Hands-on experience in Global supply chain, Regulatory, API R&D, Quality and Commercial Operations
Dr. Srihari is a PhD in Organic Chemistry from Andhra University. He has done his post-doctoral research in the US. He has over 30 years of aggregate experience in Pharmaceutical Research and Development of complex APIs and finished dosage forms. At Viyash, he is responsible for R&D, Business development and Operations.
Before Viyash, he was the Co-founder and Executive Director of Laurus Labs (till 2018), responsible for Operations, R&D, Business development and Regulatory functions as head of its API division.
Prior to Laurus, Dr. Srihari served at various leadership positions in Mayne Pharma (now acquired by Pfizer) in Australia for several years covering both Technical and Commercial roles.
Mr. Neeraj Bharadwaj is the Managing Director of Carlyle India Advisors Private Limited, focused on large growth capital and buyout opportunities across sectors in India. He is based in Mumbai.
Prior to joining Carlyle in 2012, Mr. Bharadwaj was the Managing Director with Accel Partners’ growth investing operation in India. Preceding that he was with Apax Partners for nearly 10 years – as a Partner in the U.S. and subsequently as Managing Director/Country Head for Apax in India, where he led the India operations. Investments he has been involved with include Apollo Hospitals (BSE: AHEL), Jamdat (NASDAQ: JMDT), Widerthan (NASDAQ: WTHN), NXP and others. Previously, Mr. Bharadwaj was an engagement manager at McKinsey & Co.
Mr. Bharadwaj was selected as Board Member of the Indian School of Business (ISB), a Young Global Leader of the World Economic Forum (WEF), Board Member of Olympic Gold Quest (OGQ), and Member of the Harvard Business School South Asia Advisory Board
Mr. Bharadwaj serves on the boards of Global Health Private Limited, VXI Global Solutions, Delhivery Logistics and Sequent Scientific. Mr. Bharadwaj holds an MBA with distinction from Harvard Business School, and graduated summa cum laude with a BS in economics from the Wharton School of the University of Pennsylvania.
Mr. Rahul Mukim is a Director of Carlyle India Advisors Private Limited, focused on India buyout opportunities and is based in Mumbai.
Prior to joining Carlyle, Mr. Rahul was a Director at Olympus Capital, where he looked at India focused growth investments in healthcare and financial services. Prior to that, Rahul worked at Morgan Stanley's hedge fund called Frontpoint and at ICICI venture (an India focused Private Equity Fund).
Mr. Rahul has received an MBA degree from IIM Lucknow and a degree in computer engineering from VJTI Mumbai.
Dr. Carlo is an international operations senior executive with global technical, operational, and P&L experience. He has deep expertise in designing and operating global supply chains in complex regulatory environments, leading accretive M&A activity, devising and executing value creating strategies in global markets. He currently serves on the board of several pharma and CMO companies and advises companies and investors.
In Dr. Carlo's most recent corporate position, he was Executive VP of Operations at Teva Pharmaceuticals Inc. In this role he was responsible for all Manufacturing, Technology and Capital Investments, Supply Chain, Quality and Compliance, Procurement operations, as well as the global API and CMO business. Dr. Carlo retired from this position at the beginning of 2020.
Before joining Teva Pharmaceuticals Inc. in 2012, Dr. Carlo was the President Technical Operations and Global Support Functions for Bristol Myers Squibb between 2004 and 2011, where he significantly contributed to the transformation into a focused biopharma company.
Dr. Carlo received his Doctor’s degree in Chemical Engineering, and graduated Summa Cum Laude from University of Naples − Naples, Italy.
Pradip Kanakia is a qualified Chartered Accountant of both England and Wales and India and has held leadership positions with KPMG and Price Waterhouse Chartered Accountants LLP during a career spanning 35 years.
Pradip is a strong leader and governance oriented professional with expertise in strategy, transformation, performance management, accounting, auditing, reporting, systems and controls, compliance and governance.
As a lead audit partner, he has led and signed audits of several prestigious Indian and multinational companies, across various industry sectors for 23 years. As a leader in both KPMG and Price Waterhouse, he played a major role in transforming the businesses of both the firms leading to accelerated growth and profitability by demonstrating the ability to ‘turn around’ underperforming business units with strong strategic and execution skills.
Pradip currently serves on the boards of five companies, mostly in the capacity as Chairman of the Audit Committee.
Chris is a seasoned business executive with a 25 year consistent track record of exceeding goals, developing talent, and change transformation across a variety of industry verticals: aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Over the last two decades Chris has exceeded growth goals in various roles at Curia, AMRI, Johnson & Johnson, and Dynabil Industries.
Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris joined AMRI in 2008 and quickly assumed various commercial leadership roles culminating in his role as Global Head of Sales and Marketing.
Prior to joining AMRI Chris had a successful career at Johnson & Johnson where he served in several commercial roles across J&J’s portfolio of companies. Chris led in numerous internal and external commercial capacities including sales, marketing, and sales operations. During his tenure with J&J Chris exceeded goals each year, received numerous awards including J&J’s Global Standards of Leadership award in 2008, and completed J&J’s leadership development program.
Prior to joining J&J, Chris was with Dynabil Industries, Inc. (now part of Ducommun, Inc.) an Aerospace manufacturing organization, from 1997-2001.
Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from Albany College of Pharmacy and Health Sciences.
Mrs. Gurveen Singh completed her Bachelors in Philosophy Honours from Lady Sri Ram College, Delhi University, her Post Graduate in ‘Personnel Management and Industrial Relations’ from Xavier Labour Relations Institute (XLRI), Jamshedpur, and is a specialist in Human Resource Management. With her experience spanning across 42 years in inter alia talent development and HR solutions. She retired in 2020 as the Chief Human Resources Officer (CHRO) of a FTSE 20 Company, Reckitt Benckiser PLC (RB).
She is presently an Advisor to Landmark group of industries in Dubai, UAE and also serves as an independent director on the board of Eureka Forbes Ltd. In her long tenured career, Gurveen has contributed significantly to leading companies across the consumer products and hospitality sectors with a proven track record of helping businesses thrive while undergoing complex transformations . She has had extensive experience leading complex mergers & acquisitions thereby setting them for turnaround and growth. She has also held several HR roles in the hospitality industry from 1980 to 1993, and in Reckitt Benckiser from 1993 to 2020 where she has worked in both in developing markets and developed markets across the world based out of Singapore, UK and UAE, building the performance culture and strengthening these businesses with the right talent and capability.
In a successful career spanning more than five decades, Dr. Sharma held a range of senior management positions managing operations, corporate development and executive management within the pharmaceuticals and chemicals industries. Dr. Sharma was last served in Lupin as Non-Executive Vice-Chairman.
As the Managing Director of Lupin (from 2003 to Sept, 2013) he was responsible for shaping and inking Lupin’s stupendous success; one of the architects of Lupin having achieved market leadership in key markets and businesses globally; transforming it into one of the largest and fastest growing pharmaceutical companies globally. Beginning October 2013, he was elevated to the position of Executive Vice Chairman, which he held till September 2018. He stepped out of Lupin as non-executive Vice Chairman.
Under his leadership, Lupin won the NDTV Business Leadership Awards, 2011 - Indian Pharmaceutical Company of the Year and the CNBC TV 18 India Business Leadership Awards – Outstanding Company of the Year 2014-15. Dr. Sharma was awarded the Business Today Best CEO Award as well as the Distinguished Alumnus Award of the Institute by IIT Kanpur in 2013. He was also conferred with the ICC D. M. Trivedi Lifetime Achievement Award for Contribution to Indian Chemical Industry (Management of Industry) for the year 2015.
Dr. Sharma also served as the President and Chief Executive of the life sciences and specialty group and member of the management board at RPG Enterprises Ltd, Mumbai.
Dr. Sharma is a chemical engineer from Indian Institute of Technology (IIT), Kanpur, with a post- graduate diploma in industrial management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Ph.D. in economics from IIT, Mumbai. He also holds an advanced management degree from the Harvard Business School, Boston.
Currently he holds following positions in addition to his position at Lupin.
1. Non-Executive Chairman & Independent Director, Sequent Scientific Ltd. An Indian
Animal Health major.
2. Non-Executive Chairman, Shalina Healthcare Ltd.
3. Senior Advisor Private Equity Firm
4. Adjunct Professor, School of Management, Indian Institute of Technology ( IIT ) Mumbai
5. Adjunct Professor, S P Jain Institute of Management & Research, Mumbai
Sunil Kaul is a Managing Director and Financial Services sector lead for the Carlyle Group in Asia. He also leads the Southeast Asia region for Carlyle. He is based in Singapore.
Mr. Kaul has more than 30 years of experience across private equity, corporate and consumer banking. Since joining Carlyle in 2008, he has advised on investments across the region and led several notable transactions, including investments in India Infoline, PNB Housing Finance, SBI Card and SBI Life in India, the KB Financial Group in Korea and Diamond Bank, one of Nigeria’s leading banks at the time.
Mr. Kaul is a director on the boards of PNB Housing Finance Ltd and YES Bank Ltd. He has also served on the boards of several companies, including SBI Card and India Infoline in India, Ta Chong Bank in Taiwan and Diamond Bank in Nigeria.
Prior to joining Carlyle, Mr. Kaul served as President of Citibank Japan, covering the bank's corporate and retail banking operations. He concurrently served as Chairman of Citi's credit card and consumer finance companies in Japan. He was also a member of Citi's Global Management Committee and Global Consumer Planning Group.
Mr. Kaul has lived and worked in India, the United States, Japan, Netherlands and Singapore. In his earlier roles, Mr. Kaul served as Head of Retail Banking for Citi in Asia Pacific. He has also held senior positions in Business Development for Citi's Global Transaction Services based in New York, Transaction Services Head for Citi Japan based in Tokyo and Global Cash Business Management Head for ABN Amro, based in Holland.
Mr. Kaul earned his post-graduate degree in management from Indian Institute of Management in Bangalore and a bachelor’s degree in technology from Indian Institute of Technology in Bombay.
Amit Jain is the Managing Director and Co-Head of Carlyle India Advisors. Prior to Carlyle, Mr. Jain served for ten years at Blackstone in India, most recently as Senior Managing Director in its Private Equity Group where he focused on investments in the consumer, healthcare, auto, telecom and packaging sectors as well as parts of financial services. He held board positions in numerous companies including EPL, Aakash Educational Services, Aakash Edutech, Comstar Automotive Technologies, SONA BLW Precision Forgings, FINO Payments Bank, and CMS Infosystems. Prior to Blackstone, Amit was a consultant at McKinsey & Company and started his career with Unilever in operating roles.
He holds an MBA from the Indian School of Business (ISB), Hyderabad, where he was conferred ‘ISB Scholar of Excellence’ and a B.Tech. in Mechanical Engineering from the Indian Institute of Technology (IIT), Kharagpur, where he was awarded the ‘Institute Silver Medal’ for his academic performance.
Amit was recognized by The Economic Times as one of India’s ‘40 Under Forty’ young business leaders in 2019. He was also awarded the Young Alumni Achieve Award (YAAA) by his alma mater, IIT Kharagpur.